Business Standard

Wednesday, December 25, 2024 | 11:10 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Pharma Companies

Here's why Alembic Pharma was buzzing in trade on December 20, details here

Alembic Pharma share rose after the company announced that it has received final approval from the USFDA for its ANDA Divalproex Sodium Delayed-Release Capsules USP, 125 mg

Here's why Alembic Pharma was buzzing in trade on December 20, details here
Updated On : 20 Dec 2024 | 2:09 PM IST

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market
Updated On : 19 Dec 2024 | 12:13 PM IST

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed

The uptick in Piramal Pharma share price came after domestic brokerage JM Financial initiated coverage with 'Buy' for a target price of Rs 340

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed
Updated On : 17 Dec 2024 | 11:36 PM IST

Piramal Pharma to pay $407,400 to US-based VetDC Inc to settle dispute

Piramal Pharma on Friday said it will pay USD 407,400 to US-based VetDC, Inc to settle a dispute over rejected batches of a product. Piramal Pharma Solutions Inc, a unit of the company, and VetDC, Inc have entered into a settlement agreement for an amount of USD 407,400, the drug maker said in a regulatory filing. VetDC had claimed damages on account of rejection of certain batches of product manufactured and supplied by Piramal Pharma Solutions Inc. "While the company continues to believe that its legal stand is appropriate against claims made by VetDC and maintains that it has defence to VetDC's claims of liabilities and damages, in order to solely avoid continued legal costs and uncertainties of protracted litigation, the Company and VetDC have both decided to settle," Piramal Pharma said. The company shall have no responsibility for any other costs beyond the amount of USD 407,400, it added. "This settlement will not have a significant impact on the financial position of the .

Piramal Pharma to pay $407,400 to US-based VetDC Inc to settle dispute
Updated On : 07 Dec 2024 | 12:09 AM IST

Big Pharma's bet on China biotech a rare trade bright spot amid tensions

Chinese biomedical research is on the cusp of a breakthrough just as the industry starts to face serious headwinds

Big Pharma's bet on China biotech a rare trade bright spot amid tensions
Updated On : 03 Dec 2024 | 9:23 AM IST

One dead, nine hospitalised in gas leak at pharma company in Andhra Pradesh

District Fire Officer said that one person died, and nine others are under treatment after inhaling toxic gas that leaked at Tagore Pharma in Paravada, in Anakapalli district, Andhra Pradesh

One dead, nine hospitalised in gas leak at pharma company in Andhra Pradesh
Updated On : 28 Nov 2024 | 7:50 AM IST

Glenmark Pharma Q2 profit rises on strong India business performance

The company also reported a 14.6 per cent rise in revenues in the European market to Rs 687.4 crore, while recording a 1.2 per cent revenue drop in the North America market

Glenmark Pharma Q2 profit rises on strong India business performance
Updated On : 14 Nov 2024 | 9:24 PM IST

Akums Drugs tanks 10%, falls below issue price on weak Q2 earnings

In two days, the stock price of Akums Drugs has declined 19% to Rs 645.30 and fallen below its issue price of Rs 679 per share.

Akums Drugs tanks 10%, falls below issue price on weak Q2 earnings
Updated On : 12 Nov 2024 | 12:34 PM IST

Pharma major Cipla not in the pink of health; growth challenges galore

Brokerages slash target price after subdued Q2 show

Pharma major Cipla not in the pink of health; growth challenges galore
Updated On : 30 Oct 2024 | 11:46 PM IST

Torrent Pharmaceuticals promoters sell 3% stake, raise Rs 3,087 crore

Torrent Group was actively pursuing the acquisition of Cipla and JB Chemicals and Pharmaceuticals but ultimately withdrew due to high valuations demanded by the sellers

Torrent Pharmaceuticals promoters sell 3% stake, raise Rs 3,087 crore
Updated On : 30 Oct 2024 | 11:28 PM IST

Biocon Q2 FY25 results: Net profit declines 84% to Rs 27.1 crore

Revenue driven by gains from US Oncology and Insulins franchises

Biocon Q2 FY25 results: Net profit declines 84% to Rs 27.1 crore
Updated On : 30 Oct 2024 | 9:04 PM IST

NPPA asks pharma manufacturers to cut price of 3 anti-cancer drugs

The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of customs duty exemption and GST reduction to the consumers. In line with the government's commitment to ensure the availability of drugs at affordable prices, the National Pharmaceutical Pricing Authority (NPPA) has issued an office memorandum directing the concerned manufacturers to reduce the MRP on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab. This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty, the Ministry of Chemicals and Fertilisers said in a statement. The Department of Revenue, Ministry of Finance, issued a notification dated July 23, this year reducing the customs duty to nil on the three drugs. "Accordingly, there should be a reduction in MRP of these drugs in the market and benefits of reduced taxes and duties should be passed on to the consumers,"

NPPA asks pharma manufacturers to cut price of 3 anti-cancer drugs
Updated On : 29 Oct 2024 | 4:52 PM IST

Piramal Pharma deploying $85 mn capex this fiscal: Nandini Piramal

Piramal Pharma is utilising a capex of about USD 85 million for various initiatives, including capacity expansion, maintenance and de-bottlenecking of CDMO sites, in the current fiscal, according to its Chairperson Nandini Piramal. The Mumbai-headquartered firm, which aims to cross USD 2 billion in revenue by FY30, has already invested around USD 30 million in the first half of the ongoing fiscal on the initiatives. "We expect the capex this year to be at a similar level as last year, which is about USD 85 million," Piramal told PTI in an interaction. A part of the capex is planned for the domestic market while some of it would also go into the US business, she added. "Some part of it, around USD 30 million, is maintenance capex, and the rest would go into capacity expansion in Telangana and Dahej (Gujarat) plants and also towards de-bottlenecking of some of the CDMO sites," Piramal noted. The company last week reported over four-fold increase in consolidated net profit at Rs 23 c

Piramal Pharma deploying $85 mn capex this fiscal: Nandini Piramal
Updated On : 27 Oct 2024 | 11:33 PM IST

Sun Pharma gains 3%; hits new high on UBS 'Buy' rating, sees more upside

UBS has a target price of Rs 2,450 on Sun Pharma and expects it to record the highest growth in the near-term and the medium-term via a ramp-up of the specialty drug pipelline.

Sun Pharma gains 3%; hits new high on UBS 'Buy' rating, sees more upside
Updated On : 27 Sep 2024 | 3:02 PM IST

Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings

The sector is expected to benefit from steady cash flows and low financial leverage, which will help maintain stable credit profiles, even as pharma cos pursue acquisitions in niche therapeutic areas

Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings
Updated On : 18 Sep 2024 | 4:59 PM IST

Granules tanks 16% on concerns over 6 observations issued by US FDA

More than 31 million equity shares, representing 12.89 per cent equity of the pharmaceutical company, had changed hands on the NSE till 02:08 PM.

Granules tanks 16% on concerns over 6 observations issued by US FDA
Updated On : 12 Sep 2024 | 3:04 PM IST

Strides Pharma gets shareholders' nod to set up speciality pharma CDMO

Strides Pharma Science on Wednesday said it has received approval from shareholders and secured creditors for creation of OneSource -- a specialty pharma CDMO (contract development and manufacturing organization). The company has secured the approval of its shareholders and secured creditors with overwhelming majority, along with those of OneSource Specialty Pharma and SteriScience Specialties, in meetings convened under the guidance of the National Company Law Tribunal, it said in a regulatory filing. All the secured creditors who voted on the scheme for the three companies in their respective meetings were in favour of the scheme, it added. "We believe OneSource will unlock considerable value for Strides' stakeholders upon its listing. We remain committed to delivering on this promise and express our gratitude to our shareholders and creditors for their continued trust and support," Strides Pharma Science Executive Chairperson Arun Kumar said. In September 2023, Strides announced

Strides Pharma gets shareholders' nod to set up speciality pharma CDMO
Updated On : 11 Sep 2024 | 9:17 PM IST

Entod Pharma denies false claims in media regarding PresVu Eye Drops

The company further mentioned that the opinions and claims printed in news stories do not represent Entod Pharmaceuticals

Entod Pharma denies false claims in media regarding PresVu Eye Drops
Updated On : 06 Sep 2024 | 9:52 AM IST

Glenmark to pay $25 million as part of settlement with US authorities

Glenmark Pharmaceuticals has agreed to pay USD 25 million as part of a settlement with the US Department of Justice regarding a case related to the pricing of a generic drug. Glenmark Pharmaceuticals Inc, USA, a wholly-owned subsidiary of the Mumbai-based drug maker, has agreed to pay the amount in six installments over five years, with interest on the settlement amount at a rate of 4.25 per cent per annum from May 28, 2024, the company said in a late night regulatory filing on Wednesday. The Civil Division of the US Department of Justice has concluded its False Claims Act and Anti-Kickback Statute investigation in a settlement with Glenmark Pharmaceuticals Inc, USA, it said. "The settlement amount and interest on the settlement amount constitute restitution," the drug maker said. As noted, the settlement does not contain any admission of liability by the company, except to the extent already admitted by Glenmark in the August 2023 Deferred Prosecution Agreement, it added. Last ye

Glenmark to pay $25 million as part of settlement with US authorities
Updated On : 05 Sep 2024 | 11:26 PM IST

Philips appoints Bharath Sesha as new managing director for India

At Philips, Bharath Sesha succeeds Daniel Mazon, who has moved to a global role at Philips headquarters in the Netherlands

Philips appoints Bharath Sesha as new managing director for India
Updated On : 02 Sep 2024 | 4:55 PM IST